header logo image


Page 762«..1020..761762763764..770780..»

Study ties gene active in developing brain to autism – Spectrum

January 6th, 2020 4:43 pm

Puzzling injury: Some children who carry variants in a gene called ZNF292 have injured blood vessels in their brains.

Mutations in a gene called ZNF292 lead to a variety of developmental conditions, including autism and intellectual disability, according to a new study1.

ZNF292 encodes a protein that influences the expression of other genes. It is highly expressed in the developing human brain, particularly in the cerebellum, an area that controls voluntary movement and contributes to cognition. However, its function in neurodevelopment is unknown.

Scientists first linked ZNF292 to intellectual disability in a 2012 study. A 2018 analysis of five ZNF292 variants tied the gene to autism, but the work was preliminary2.

In the new study, researchers identified 28 people who have mutations in ZNF292. The participants come from six countries and are between 10 months and 24 years old. The group carries a total of 24 mutations in the gene, 23 of which are spontaneous meaning that they were not inherited from a parent.

The sheer number of families and children that have been identified so far has been quite high, says Ghayda Mirzaa, lead investigator and assistant professor of genetic medicine at Seattle Childrens Hospital in Washington.

All but one of the participants have intellectual disability. In total, 17 of the participants are suspected or confirmed to have autism and 9 are suspected or confirmed to have attention deficit hyperactivity disorder. All but two have speech delays, and four have had language regression or are minimally verbal.

Mirzaas team found an additional 15 people with mutations in the gene from 12 families. However, the data from these people were incomplete, so the researchers had to exclude them from the analysis. The team has connected with at least 10 other mutation carriers in the six weeks since the study was published in Genetics in Medicine.

The researchers have used their data to classify a new condition. However, it may be premature to call it a syndromic form of autism or intellectual disability, says Holly Stessman, assistant professor of pharmacology and neuroscience at Creighton University in Omaha, Nebraska, who was not involved in the work.

People with ZNF292 variants have a broad spectrum of physical traits. For instance, 11 of the people in the study have growth abnormalities such as short stature; 10 have low muscle tone; and 3 have stiff or mixed muscle tone. The researchers had access to magnetic resonance imaging scans for 17 of the participants: 9 show brain abnormalities such as atypically shaped regions, and 3 of those 9 appear to have blood-vessel injuries in the brain.

Nearly half of the participants also have unusual facial characteristics, including an undersized jaw or eyes that are unusually far apart. Vision problems, such as involuntary eye movement or crossed eyes, affect nine people in the group. Less common facial differences include prominent incisors and protruding ears.

Autism genes are often linked to a wide range of characteristics, says Santhosh Girirajan, associate professor of biochemistry and molecular biology at Pennsylvania State University, who was not involved in the study. Variability has become the rule now, rather than the exception, he says.

Mirzaa says her group plans to study more individuals with variants in ZNF292, and to investigate the genes function.

Link:
Study ties gene active in developing brain to autism - Spectrum

Read More...

New MD Treatments the Main Goal of Astellas, Audentes Merger – Muscular Dystrophy News

January 6th, 2020 4:43 pm

Astellas Pharma recentlyagreed to acquire Audentes Therapeutics, a move it expects will result in faster development of potentially best-in-class therapies for rare neuromuscular diseases, including muscular dystrophy (MD).

Audentes vectorized exon-skipping technology which uses a modified adeno-associated virus (AAV) vector to allow cells to skip over mutated sections of genes will complement Astellas own work, Kenji Yasukawa, president and CEO of Astellas, said in a press release.

Recent scientific and technological advances in genetic medicine have advanced the potential to deliver unprecedented and sustained value to patients, and even to curing diseases with a single intervention, Yasukawa said.

Audentes has developed a robust pipeline of promising product candidates which are complementary to our existing pipeline, including its lead program AT132, he added. By joining together with Audentes talented team, we are establishing a leading position in the field of gene therapy with the goal of addressing the unmet needs of patients living with serious, rare diseases.

The technology uses the modified AAV vector to deliver small molecules antisense oligonucleotides complementary to the RNA sequence of a gene of interest, which allow cells to skip over mutated exons while they are producing proteins.

Exons are the coding regions of genes that provide instructions to make proteins.

Audentes had started developing several therapies for Duchenne muscular dystrophy (DMD) based on its exon-skipping technology. These include AT702, AT751 and AT753.

All three treatment candidates use the same AAV delivery vector. However, as they target different DMD gene exons, the potential therapies are intended for distinct subgroups of patients. AT702 is designed to skip exon 2 and is meant for those who either have duplications in exon 2 or mutations in exons 1-5. AT751 is designed for those with mutations in exon 51, and AT753 for people with alterations in exon 53.

Audentes had also started developing and testing AT466, an experimental treatment for myotonic dystrophy type 1.

The acquisition also gives Astellas direct access to AT132, Audentes lead gene therapy candidate for the treatment ofX-linked myotubular myopathy.

AT132 uses an AAV8 viral vector to deliver a functional copy of the MTM1 gene to muscle cells. This enables the production of myotubularin, an important enzyme for the development and maintenance of muscle cells.

Matthew R. Patterson, chairman and CEO of Audentes, said his company is very pleased with the agreement. With its focus on innovative science and a global network of research, development and commercialization resources, we believe that operating as part of the Astellas organization optimally positions us to advance our pipeline programs and serve our patients, he said.

Under the terms of the agreement, Audentes will become an independent subsidiary of Astellas and will have access to scientific resources to accelerate the development and manufacturing of the combined product pipeline. The transaction, worth $3 billion, is expected to take place early this year.

Joana is currently completing her PhD in Biomedicine and Clinical Research at Universidade de Lisboa. She also holds a BSc in Biology and an MSc in Evolutionary and Developmental Biology from Universidade de Lisboa. Her work has been focused on the impact of non-canonical Wnt signaling in the collective behavior of endothelial cells cells that make up the lining of blood vessels found in the umbilical cord of newborns.

Total Posts: 42

Jos is a science news writer with a PhD in Neuroscience from Universidade of Porto, in Portugal. He has also studied Biochemistry at Universidade do Porto and was a postdoctoral associate at Weill Cornell Medicine, in New York, and at The University of Western Ontario in London, Ontario, Canada. His work has ranged from the association of central cardiovascular and pain control to the neurobiological basis of hypertension, and the molecular pathways driving Alzheimers disease.

Read the rest here:
New MD Treatments the Main Goal of Astellas, Audentes Merger - Muscular Dystrophy News

Read More...

Insights on precision oncology developments in Japan and beyond – MobiHealthNews

January 6th, 2020 4:43 pm

Cancer has been the leading cause of death in Japan since 1981 and this is compounded by the fact that the country has a hyper-aging society, which means that Japan will face a substantial increase in the number of elderly cancer patients, according to a review article by Matsuda and Saika published in the Annals of Cancer Epidemiology in 2018. Prof Yasushi Goto of the National Cancer Center Hospital in Japan shared with MobiHealthNews on some of the latest developments in precision oncology in Japan, the interest of pharmaceutical companies in targeted therapy and a nationwide cancer genome screening project named SCRUM.

Q. Could you tell us more about your role at the National Cancer Center Hospital?

A. National Cancer Center Hospital (NCCH) is based in Tokyo, Japan and is the largest cancer center in the country. The other is national cancer center is located in Chiba, Japan. One of the special characteristics of NCCH apart from the research institute hospital, is that we also do research for every kind of cancer activity in our hospital. We dont only do clinics, but also genetic oncology, rare cancers.

My main work is at thoracic oncology which mainly covers lung cancer. I also am a member of Rare Cancer Center so I also cover, malignant mesothelioma, thymic cancer, neuroendocrine tumors, and all others. Since Japan has launched national genomic project, and National Cancer Center is playing the central role in this project, I am also joining Section of Knowledge Integration in Center for Cancer Genomics and Advanced Therapeutics.

Q. What are your observations on the development of precision oncology in the APAC region? How would you describe precision oncology in the most straightforward manner?

A. Testing for patients with cancer is prevalent in the APAC region. Compared to other countries, people in Asia are generally accustomed to genetic testing for precision medicine. Our capabilities may not be as advanced as the United States for full gene sequencing, perhaps because of cost issues, but we are catching up.

For precision oncology to develop further, more patients should be tested for genetic testing and target therapy. We are looking to putting in place a proper system to support this right now, especially in the rare cancer field.

There was a recent nationwide project in Japan called SCRUM, conducted by the National Cancer Center East Hospital. SCRUM is the first industry-academia collaboration nationwide cancer genome screening project. I believe early access to drugs is partly due to this project.

Q. Medtech or healthtech startups are also getting into the precision medicine space and seeing a lot of interest from investors. For instance, genomic medicine startup Lucence from Singapore recently raised $20 million in Series A funding. What opportunities do you see in these startups in terms of working together with hospitals such as the National Cancer Centre Hospital? Are there any notable startups in Japan in the precision medicine space?

A. In Japan, many pharmaceutical companies are looking at targeted therapy. Prominent companies include Daichi-Sankyo, Chugai, and Takeda. NCCH is currently working closely with Daichi-Sankyo, Takeda and Chugai.

The approval system is different between blockbuster drugs and targeted therapy. If you only have one patient in Japan and globally there are only 20 or so there can be a scenario where the drug is effective, but it is not approved in our country as there is only a single patient. This is why some pharmaceutical companies are looking at precision medicine.

Companies including Sysmex are also actively looking into the testing of panel sequencing. NCCH has also worked with Sysmex to make a cancer sequencing panel.

Q. The high incidence of cancer in modern societies is worrying and also very costly how do you think precision oncology can help tackle some of these challenges?

A. Cost is a global issue, for both the development side (e.g. the pharmaceutical companies) and the consumption side (e.g. governments, individuals). We also need some basic infrastructure for precision oncology, to screen patients. Currently each drug needs its own testing. With many drugs that need to be tested, we need a platform to do panel sequencing in order to annotate any genetic changes in the patients for treatment.

In Japan, we are now trying to make this infrastructure because the government recently approved the panel sequencing in 2019. This means that after standard therapy, every patient is able to test for panel sequencing. As more patients are screened, in this way I think cancer treatment will be improved in the future.

Q. What do you think will be the key developments and breakthroughs in precision oncology in the next 3-5 years?

A. There will be no blockbuster development, but there will be steady progress in the detecting genetic changes earlier in the next 3-5 years. Some of the topics at the ESMO Asia Congress 2019 in Singapore were on advancements in detecting mutations/previously overlooked genes. Since we are able to find these abnormalities earlier, we now have new anti-cancer agents to target them.

Follow this link:
Insights on precision oncology developments in Japan and beyond - MobiHealthNews

Read More...

New Publication Demonstrates GeneSight Improved All Clinical Outcomes Using HAM-D6 Analysis in Large Prospective GUIDED Study – Associated Press

January 6th, 2020 4:43 pm

SALT LAKE CITY, Jan. 06, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN, Myriad or the Company), a global leader in molecular diagnostics and precision medicine, announced that a new analysis of the GUIDED1 clinical trial using the 6-item Hamilton Depression Rating Scale (HAM-D6) was published online in BMC Psychiatry. The key finding is the HAM-D6 scale identified statistically significant improvements in all three clinical endpoints remission, response and symptoms between GeneSight-guided care and treatment-as-usual at Week 8 (Figure 1).

The HAM-D6 scale has been shown to be a better measure of core depressive symptoms than the HAM-D17 scale, said Boadie W. Dunlop, M.D., one of the study investigators and associate professor of Psychiatry and Behavioral Sciences at Emory University School of Medicine. This post hoc analysis provides further evidence that the GeneSight test led to significant and clinically meaningful improvements in clinical outcomes for patients with major depressive disorder relative to treatment-as-usual care.

To view Figure 1: GeneSight Test Significantly Improved Clinical Outcomes by Week 8 (HAM-D6), please visit the following link: https://www.globenewswire.com/NewsRoom/AttachmentNg/980daabb-fd8c-4bbb-b56e-48795fa16bdb

The GUIDED study was the largest prospective study to assess the benefit of pharmacogenomics-guided treatment for depression using the GeneSight Psychotropic test versus an active therapy control arm. All patients in the GUIDED study had the 17-item HAM-D17 questionnaire administered by blinded off-site raters as part of the study protocol. The 6-item HAM-D6 score represents a subset of HAM-D17 questions that have been shown to be more directly linked to depression. For example, questions such as have you had trouble sleeping which could be associated with conditions other than depression are excluded from the HAM-D6 score. Clinical studies have shown that the HAM-D6 score is superior to HAM-D17 at discriminating antidepressants from placebo.

About GeneSight PsychotropicGeneSight Psychotropic is a pharmacogenomic test that analyzes clinically important variations in DNA. The results of the test can inform doctors about genes that may impact how their patients metabolize or respond to depression medications.

About Myriad GeneticsMyriad Genetics Inc., is a leading precision medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics. Myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs. Myriad is focused on five critical success factors: building upon a solid hereditary cancer foundation, growing new product volume, expanding reimbursement coverage for new products, increasing RNA kit revenue internationally and improving profitability with Elevate 2020. For more information on how Myriad is making a difference, please visit the Companys website: http://www.myriad.com.

Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris AP, myPath, myRisk, Myriad myRisk, myRisk Hereditary Cancer, myChoice, myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice CDx, EndoPredict, Vectra, GeneSight, riskScore, Prolaris, ForeSight and Prequel are trademarks or registered trademarks of Myriad Genetics, Inc. or its wholly owned subsidiaries in the United States and foreign countries. MYGN-F, MYGN-G.

Safe Harbor StatementThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to a new analysis of the GUIDED clinical trial published online in BMC Psychiatry; and the Companys strategic directives under the caption About Myriad Genetics. These forward-looking statements are based on managements current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by forward-looking statements. These risks and uncertainties include, but are not limited to: the risk that sales and profit margins of our molecular diagnostic tests and pharmaceutical and clinical services may decline; risks related to our ability to transition from our existing product portfolio to our new tests, including unexpected costs and delays; risks related to decisions or changes in governmental or private insurers reimbursement levels for our tests or our ability to obtain reimbursement for our new tests at comparable levels to our existing tests; risks related to increased competition and the development of new competing tests and services; the risk that we may be unable to develop or achieve commercial success for additional molecular diagnostic tests and pharmaceutical and clinical services in a timely manner, or at all; the risk that we may not successfully develop new markets for our molecular diagnostic tests and pharmaceutical and clinical services, including our ability to successfully generate revenue outside the United States; the risk that licenses to the technology underlying our molecular diagnostic tests and pharmaceutical and clinical services and any future tests and services are terminated or cannot be maintained on satisfactory terms; risks related to delays or other problems with operating our laboratory testing facilities and our healthcare clinic; risks related to public concern over genetic testing in general or our tests in particular; risks related to regulatory requirements or enforcement in the United States and foreign countries and changes in the structure of the healthcare system or healthcare payment systems; risks related to our ability to obtain new corporate collaborations or licenses and acquire new technologies or businesses on satisfactory terms, if at all; risks related to our ability to successfully integrate and derive benefits from any technologies or businesses that we license or acquire; risks related to our projections about our business, results of operations and financial condition; risks related to the potential market opportunity for our products and services; the risk that we or our licensors may be unable to protect or that third parties will infringe the proprietary technologies underlying our tests; the risk of patent-infringement claims or challenges to the validity of our patents or other intellectual property; risks related to changes in intellectual property laws covering our molecular diagnostic tests and pharmaceutical and clinical services and patents or enforcement in the United States and foreign countries; risks of new, changing and competitive technologies and regulations in the United States and internationally; the risk that we may be unable to comply with financial operating covenants under our credit or lending agreements; the risk that we will be unable to pay, when due, amounts due under our credit or lending agreements; and other factors discussed under the heading Risk Factors contained in Item 1A of our most recent Annual Report on Form 10-K for the fiscal year ended June 30, 2019, which has been filed with the Securities and Exchange Commission, as well as any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. All information in this press release is as of the date of the release, and Myriad undertakes no duty to update this information unless required by law.

Media Contact: Ron Rogers Investor Contact: Scott Gleason (801) 584-3065 (801) 584-1143 rrogers@myriad.com sgleason@myriad.com

1 Greden JF, Parikh SV, Rothschild AJ, et al. Impact of pharmacogenomics on clinical outcomes in major depressive disorder in the GUIDED trial: A large, patient- and rater-blinded, randomized, controlled study. J Psychiatr Res. 2019; 111:59-67.

See the original post here:
New Publication Demonstrates GeneSight Improved All Clinical Outcomes Using HAM-D6 Analysis in Large Prospective GUIDED Study - Associated Press

Read More...

These 2 Stocks Will Fall After the New Year – Nasdaq

January 6th, 2020 4:43 pm

For all of the hype surrounding gene therapy and gene editing, the precision genetic medicine approach that turned in the best 2019 may have been RNA interference (RNAi). The gene-silencing technique earned its first regulatory approval for a novel targeted delivery method. That may not sound like much to get excited about, but it promises to open up numerous high-value opportunities for RNAi drug developers.

The approval, coupled with promising early-stage clinical results and massive partnership deals, explains why Arrowhead Pharmaceuticals (NASDAQ: ARWR) and Dicerna Pharmaceuticals (NASDAQ: DRNA) erupted higher in 2019. The RNAi drug developers saw their market valuations increase by 450% and 106%, respectively, last year.

While both companies have promise, thepharma stocks are likely to fall in early 2020. What does that mean for investors with a long-term mindset?

Image source: Getty Images.

Shares of Arrowhead Pharmaceuticals had a pretty good first nine months of 2019, but the most impressive gains came in the fourth quarter. The RNAi stock gained heading into the American Association for the Study of Liver Diseases (AASLD) Annual Meeting in November. Investors were eagerly awaiting the results of two drug combinations being developed to treat chronic hepatitis B (CHB) by Johnson & Johnson (NYSE: JNJ) subsidiary Janssen.

The results lived up to the hype. The most impressive data came from a triple combination of an RNAi drug from Arrowhead Pharmaceuticals (now called JNJ-3989), an antiviral drug from Johnson & Johnson (JNJ-6379), and a nucleos(t)ide analog (NA). After 16 weeks of treatment, all 12 individuals in the study achieved at least a 90% reduction in two biomarkers of hepatitis B virus activity.

Investors gobbled up shares of Arrowhead Pharmaceuticals because the triple combination appears to be the industry's best hope for developing the first functional cure for CHB (although it can't be called a functional cure just yet).

Additionally, the RNAi drug candidate in the triple combination is based on a targeted delivery platform called TRiM. The approach is simple: The gene-silencing payload is attached to a special sugar that's absorbed by the liver. Since many RNAi drug candidates need to interact with DNA in liver cells, and the sugars are easily metabolized by the liver (improving safety over prior-generation lipid nanoparticle delivery vehicles), it's a perfect pairing.

It helps that just a few weeks after AASLD, Givlaari from Alnylam Pharmaceuticals (NASDAQ: ALNY)became the first RNAi drug candidate based on a conjugated-sugar delivery method to earn regulatory approval. It also helps that Dicerna Pharmaceuticals landed two massive partnerships in the fourth quarter of 2019 -- both based on its own conjugated-sugar delivery platform. Following those deals, there's now considerable overlap between the pipelines of Arrowhead Pharmaceuticals and Dicerna Pharmaceuticals, which are both all-in on targeted delivery.

RNAi Developer

Partner, Indication

Financial Terms

Arrowhead Pharmaceuticals

Johnson & Johnson, hepatitis B

$175 million up front, $75 million equity investment, up to $1.6 billion in milestone payments, royalties

Arrowhead Pharmaceuticals

Johnson & Johnson, undisclosed

Up to $1.9 billion in total milestone payments for up to three additional drug candidates, royalties

Arrowhead Pharmaceuticals

Amgen, cardiovascular disease

$35 million up front, $21.5 million equity investment, up to $617 million in milestone payments, royalties

Dicerna Pharmaceuticals

Roche, hepatitis B

$200 million up front, up to $1.47 billion in milestone payments, royalties

Dicerna Pharmaceuticals

Novo Nordisk, various liver-related cardio-metabolic diseases

$175 million up front, equity investment of $50 million, an additional $75 million over the first three years, up to $357.5 million per drug candidate, royalties

Data source: Press releases, filings with the Securities and Exchange Commission.

Despite all of the progress from both Arrowhead Pharmaceuticals and Dicerna Pharmaceuticals in 2019, both companies are likely to fall back to Earth a bit following giant run-ups.

Consider that Arrowhead Pharmaceuticals is valued at $6.3 billion at the start of 2020. The company's most advanced drug candidate, ARO-AAT, recently began dosing patients in a phase 2/3 trial in a rare genetic liver disease associated with alpha-1 antitrypsin (AAT or A1AT) deficiency. While that study can be used for a new drug application (NDA), and the drug candidate could achieve over $1 billion in peak annual sales, that alone doesn't support a $6.3 billion valuation.

Meanwhile, the triple combination in CHB could support a market valuation well above $6 billion, especially if it proves to be a functional cure. The drug candidate could eventually earn peak annual sales of over $10 billion in that scenario. But the recent gains were spurred by results in only 12 individuals after 16 weeks of follow-up. A phase 2b trial now underway will enroll 450 patients and follow them for two years. In other words, there's plenty of time for investors to take some gains off the table.

Dicerna Pharmaceuticals is valued a little more reasonably, at just $1.5 billion, but it has only one drug candidate in mid- or late-stage clinical trials. The pipeline programs at the center of recent deals with Roche and Novo Nordisk are still in preclinical development or phase 1 studies; there's little to no clinical data from the programs for investors to survey. While the business will be flush with cash after receiving up-front payments in the coming months, there's a lot of work to be done.

To be clear, both Arrowhead Pharmaceuticals and Dicerna Pharmaceuticals hold a lot of promise. Targeted delivery of RNAi drug payloads into the liver could open up considerable opportunities to treat -- for the first time, in some cases -- rare diseases, viral infections, and cardiovascular ailments. Both companies have even demonstrated early work to target gene-silencing payloads to other cell types, such as muscle tissues, which may open up additional avenues for drug discovery and development.

However, these two RNAi stocks have fallen 10.7% and 12.3%, respectively, since Dec. 3 -- and both are likely to fall a bit further in early 2020. If and when that occurs, investors may want to give each stock, especially Arrowhead Pharmaceuticals, a closer look.

10 stocks we like better than Johnson & JohnsonWhen investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*

David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Johnson & Johnson wasn't one of them! That's right -- they think these 10 stocks are even better buys.

See the 10 stocks

*Stock Advisor returns as of December 1, 2019

Maxx Chatsko has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Alnylam Pharmaceuticals. The Motley Fool recommends Amgen, Johnson & Johnson, and Novo Nordisk. The Motley Fool has a disclosure policy.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

See the original post:
These 2 Stocks Will Fall After the New Year - Nasdaq

Read More...

New protocol could signal shift in bone regenerative medicine – Yahoo Finance

January 6th, 2020 4:43 pm

A new, safe and efficient way to coax stem cells into bone cells is reported in a recently published article from STEM CELLS Translational Medicine (SCTM).

DURHAM, N.C., Jan. 6, 2020 /PRNewswire-PRWeb/ -- A new, safe and efficient way to coax stem cells into bone cells is reported in a recently published article from STEM CELLS Translational Medicine (SCTM). The protocol, developed by researchers at the University of Sydney, Australian Research Centre (ARC) for Innovative BioEngineering, could lead to a shift in the treatment of bone regenerative medicine.

Large bone defects and loss due to cancer or trauma can result in scar tissue that impairs the bones' ability to repair and regenerate. The current gold standard therapy, autografting, has inherent drawbacks, including limited availability and donor site morbidity. This leaves researchers seeking an alternative source of bone cells and makes bone tissue engineering a growing field with considerable translational potential.

"The success of induced pluripotent stem cell (iPSC) technology to reprogram fibroblasts into progenitor cells of various lineages offers an exciting route for tissue repair and regeneration," said Zufu Lu, Ph.D., a member of the University of Sydney's Biomaterials and Tissue Engineering Research Unit and a research associate at the ARC for Innovative BioEngineering. He is a co-lead investigator of the SCTM study, along with Professor Hala Zreiqat, Ph.D., head of the research unit and director of the ARC Training Centre for Innovative BioEngineering.

"However, while iPSC technology represents a potentially unlimited source of progenitor cells and allows patients to use their own cells for tissue repair and regeneration thus posing little or no risk of immune rejection the technology has several constraints. Among them are the requirement for complex reprogramming using the Yamanaka factors (Oct3/4, Sox2, Klf4, c-Myc). To add to the complexity, specific stimuli are required to direct iPSCs to re-differentiate to progenitor cells of the lineage of interest.

"In addition," Dr. Lu said, "any remaining iPSCs pose the risk of tumors following implantation."

One potential way around this, as demonstrated by recent studies, is through the direct reprogramming of fibroblasts into bone cells. "Fibroblasts are morphologically similar to osteoblasts. Their similar transcriptomic profiles led us to hypothesize that distinct factors produced by osteoblasts may be capable of coaxing fibroblasts to become osteoblast-like cells," Prof. Zreiqat said.

Previous studies aimed at using fibroblasts to produce various cell types relied on the genetic manipulation of one or more transcription regulators. But just as with iPSCs, reprogramming fibroblasts in this manner has its own inherent technical and safety issues. The Lu-Zreiqat team, however, surmised that an approach employing natural factors might just allow better control over reprogramming and improve the safety.

"Unlike genetic reprogramming, chemical induction of cell reprogramming is generally rapid and reversible, and is also more amenable to control through factor dosage and/or combinations with other molecules," Dr. Lu explained.

The team initially determined that media conditioned by human osteoblasts can induce reprogramming of human fibroblasts to functional osteoblasts. "Next," said Prof. Zreiqat, "our proteomic analysis identified a single naturally bioactive protein, insulin growth factor binding protein-7 (IGFBP7), as being significantly elevated in media conditioned with osteoblasts, compared to those with fibroblasts."

This led them to test IGFBP7's ability as a transcription factor. They found it, indeed, successfully induced a switch from fibroblasts to osteoblasts in vitro. They next tested it in a mouse model and once again experienced success when the fibroblasts produced mineralized tissue. The switch was associated with senescence and dependent on autocrine IL-6 signaling.

"The approach we describe in our study has significant advantages over other commonly used cell sources including iPSCs and adult mesenchymal stem cells," Dr. Lu and Prof Zreiqat concluded.

"Bone tissue engineering is a growing field where cell therapies have considerable translational potential, but current cell-based approaches face limitations," said Anthony Atala, M.D., Editor-in-Chief of STEM CELLS Translational Medicine and director of the Wake Forest Institute for Regenerative Medicine. "The novel observation described in this study could potentially lead to a shift in the current paradigm of bone regenerative medicine."

Story continues

This study was conducted in collaboration with the Charles Perkins Centre and the Children's Hospital at Westmead, University of Sydney.

The full article, "Reprogramming of human fibroblasts into osteoblasts by insulin-like growth factor binding protein 7," can be accessed at https://stemcellsjournals.onlinelibrary.wiley.com/doi/abs/10.1002/sctm.19-0281.

About STEM CELLS Translational Medicine: STEM CELLS Translational Medicine (SCTM), co-published by AlphaMed Press and Wiley, is a monthly peer-reviewed publication dedicated to significantly advancing the clinical utilization of stem cell molecular and cellular biology. By bridging stem cell research and clinical trials, SCTM will help move applications of these critical investigations closer to accepted best practices. SCTM is the official journal partner of Regenerative Medicine Foundation.

About AlphaMed Press: Established in 1983, AlphaMed Press with offices in Durham, NC, San Francisco, CA, and Belfast, Northern Ireland, publishes two other internationally renowned peer-reviewed journals: STEM CELLS (http://www.StemCells.com), celebrating its 38th year, is the world's first journal devoted to this fast paced field of research. The Oncologist (http://www.TheOncologist.com), also a monthly peer-reviewed publication, entering its 25th year, is devoted to community and hospital-based oncologists and physicians entrusted with cancer patient care. All three journals are premier periodicals with globally recognized editorial boards dedicated to advancing knowledge and education in their focused disciplines.

About Wiley: Wiley, a global company, helps people and organizations develop the skills and knowledge they need to succeed. Our online scientific, technical, medical and scholarly journals, combined with our digital learning, assessment and certification solutions, help universities, learned societies, businesses, governments and individuals increase the academic and professional impact of their work. For more than 200 years, we have delivered consistent performance to our stakeholders. The company's website can be accessed at http://www.wiley.com.

About Regenerative Medicine Foundation (RMF): The non-profit Regenerative Medicine Foundation fosters strategic collaborations to accelerate the development of regenerative medicine to improve health and deliver cures. RMF pursues its mission by producing its flagship World Stem Cell Summit, honouring leaders through the Stem Cell and Regenerative Medicine Action Awards, and promoting educational initiatives.

SOURCE STEM CELLS Translational Medicine

More here:
New protocol could signal shift in bone regenerative medicine - Yahoo Finance

Read More...

Professors Sally Davies and Lesley Regan recognised in New Year’s Honours – BioNews

January 6th, 2020 4:43 pm

6 January 2020

Leading figures in science and healthcare have been recognised in the UK's New Year's Honours list 2020.

Professor Dame SallyDavies received Dame Grand Cross of the Order of the Bath (GCB) for services to public health and research, having previously been made a Dame in 2009. Dame Sally was Chief Medical Officer for England from 2010-2019. Her initiatives included the 'Generation Genome' report (see BioNews908) which recommended widespread adoption of genomic medicine within the NHS, as well as ongoing efforts to combat antimicrobial resistance.

'I am honoured to receive this GCB recognising the efforts of many people across Government, the NHS and beyond, working together on issues ranging through health research and public health to fighting the rise of antimicrobial resistance both in the UK and across the world. We willcontinue to build coalitions for action as this war to save lives is not over' she said.

Professor Lesley Regan who stepped down as President, Royal College of Obstetricians and Gynaecologists (RCOG) in December, was made a Dame 'for services to women's healthcare'.

'I am delighted and honoured to be recognised in the New Year Honours. The progress we have made in women's health at the RCOG is only possible because of the hard work and commitment of the wonderful staff and our wider membership. We have much work to do to achieve the aims set out in the Better for Women report and I look forward to supporting the RCOG and its many key partners to transform healthcare services for women and girls.'

Other honours included a knighthood for Genomics England's former chair, Jonathan Symonds for services to UK life sciences and finance.

Professor Alan Lehmann, Research Professor of Molecular Genetics, University of Sussex received a CBE for services to medical science, patients and families affected by the genetic conditions xeroderma pigmentosum and Cockayne syndrome.

OBEs were awarded to Professor Sheila McLean, the University of Glasgow's Professor Emerita of Law and Ethics in Medicine for services to health and education and to former director of the Academy of Medical Sciences Dr Helen Munn for services to the advancement of medical science.

Nicola Perrin, former head of the Wellcome Trust's Understanding Patient Data programme received an MBE for services to science.

Follow this link:
Professors Sally Davies and Lesley Regan recognised in New Year's Honours - BioNews

Read More...

NuProbe Global and CarrierGene Biotech Co. Ltd. Announced Completion of Merger, Appointed Yingshuang Chai as CEO, and Established Collaboration with…

January 6th, 2020 4:43 pm

NuProbe Global and CarrierGene Biotech Co. Ltd. (Suzhou, China) announced the successful completion of their recent merger and integration. The new company will operate under the English brand NuProbe Global and the Chinese brand (Yue Er).

We are very excited about the merger between NuProbe and CarrierGene, said Yingshuang Chai, who is the co-founder and former CEO of CarrierGene and now serves as CEO and Chairman of the Board of Directors of the merged NuProbe.

Mr. Chai is a renowned expert in the genomics industry with nearly 20 years of success and rich experience in market operation. He is the former national clinical business director of Life Technologies China and the former national director of clinical strategy & development of Thermo Fisher China.

I am greatly impressed by NuProbes technology, which is highly differentiated with unique features that are hard to mimic using alternative methods. The platform innovation can break through the current bottlenecks of the clinical genetic testing and enable new business models, Chai continued. After the merger, NuProbe will have exceptional research and commercial teams in both the United States and China. In addition to new products to be deployed in the US, China, and the Asia-Pacific region, our technology can help other genomics companies achieve better technical performance, go beyond homogenous competition, and accelerate the expansion of the entire genomics diagnostic market. In the past six months, we have completed the integration of the two companies products, finances, teams, and business, and made breakthrough progress with the development of new products.

NuProbe has several groundbreaking cross-platform molecular technologies that greatly improve the technical performance of different molecular diagnostic platforms. CarrierGene has been a pioneer and leader in the blue ocean market of infertility gene testing in the field of reproductive health. The merged NuProbe will accelerate the commercialization of various cutting-edge technologies, empower existing technology platforms and business partners, create more products adapted to clinical applications, and enable new advances in the genomics market. The merged NuProbe will have research and development (R&D) laboratories in Houston, TX and Shanghai, China, as well as a Good Manufacturing Practice (GMP) production facility in Suzhou, China.

Mr. Chai is an amazing entrepreneur with a precise and profound understanding of the Chinese genomics industry after years of immersion, and extraordinary insights and vision. I look forward to seeing NuProbe grow into a great enterprise under his leadership and contributing to the molecular diagnostics industry in China and around the world, said Peng Yin, Ph.D., co-founder of NuProbe, who is also a professor of systems biology at Harvard Medical School and a core faculty member of the Wyss Institute for Biologically Inspired Engineering at Harvard University.

Both our R&D teams and commercial teams have enjoyed working together as business partners in the past year, and the formal merger will allow closer and more efficient collaboration, said David Zhang, Ph.D., co-founder of and head of innovation at NuProbe, and associate professor of bioengineering at Rice University.

Yundi Chen, Ph.D., co-founder of and CTO at CarrierGene, added: NuProbes technologies not only have strong applications in cancer, but are also well suited for many clinical challenges in genetic diseases and reproductive health. This merger will allow our two companies to more effectively penetrate our respective core markets while opening up new opportunities.

The synergy between NuProbes technology and CarrierGenes commercial team is formidable. I am very happy to support the founding of NuProbe and facilitate the merger of NuProbe and CarrierGene. With the completion of the merger, we are optimistic that NuProbe will become an innovative diagnostic company rooted in China and leading the world, said Kevin Chen, founding partner of BioTrack Capital and a member of the Board of Directors of the merged NuProbe. BioTrack is enthusiastic to support the merged NuProbe with an initial investment.

The investment by BioTrack Capital will support R&D in new product development, filing of NMPA (Chinas equivalent of FDA) registrations for in vitro diagnostic products, and commercial team buildout.

We believe that the merged NuProbe will rapidly realize the commercialization of its world-leading core technology. We are optimistic about the companys prospects, and fully support Mr. Chai and his team, said Trency Gu, managing director at Sequoia Capital China and a member of the Board of Directors of NuProbe.

Ms. Gu will continue to serve as a member of the Board of Directors of the merged NuProbe.

The revolutionary technologies developed by NuProbe will be strong assets for the merged company, said Dongmei Ji, founding partner at GP Healthcare Capital. GP Healthcare Capital is one of the Pre-A investors of CarrierGene and has appointed Ms. Xiaoyan Wang as a member of the Board of Directors of the merged NuProbe.

NuProbes technology is widely recognized for its innovation and unique capabilities. The merger with CarrierGene will result in more products that benefit patients in a wider range of disease indications, said David R. Walt, Ph.D., member of the National Academy of Engineering and the National Academy of Medicine, co-founder of Illumina, professor of pathology at Harvard Medical School, and a core faculty member of the Wyss Institute at Harvard University.

We look forward to continuing to support the merged NuProbe in driving more technology innovations to improve human health, Dr. George Church,

member of the National Academy of Sciences and the National Academy of Engineering, professor of genetics at Harvard Medical School, and a core faculty member of the Wyss Institute, added.

Both Dr. Walt and Dr. Church will continue to serve on the Scientific Advisory Board of the merged NuProbe.

In addition, the merged NuProbe has executed a contract for a strategic partnership with Illumina in late 2019. NuProbe and Illumina will work together in the field of clinical NGS testing for infertility and other genetic diseases. As part of the collaboration, NuProbe will develop clinical molecular diagnostic kits, including for nucleic acid extraction, library construction, and bioinformatic software. The kits will be used on Illuminas NGS instruments, and the two companies will seek regulatory approval from NMPA. Further potential collaborations between NuProbe and Illumina are in discussions.

To learn more about NuProbe, please visit http://www.nuprobe.com.

About NuProbe Global

NuProbe Global is a biotech company founded by world-class scientists in 2016, building initially on several technologies exclusively licensed from Harvard University and Rice University, and financed by prestigious institutional investors such as Sequoia Capital China. NuProbe possesses a number of revolutionary molecular diagnostics technologies, and collaborates with many renowned academic institutions, medical institutions, and companies worldwide. It has subsidiaries in Houston, USA and Suzhou, China. http://www.nuprobe.com

About CarrierGene Biotech Co. Ltd.

Founded in 2016, CarrierGene was co-founded by former senior employees from first-line companies in the genomics industry such as Thermo Fisher, Illumina and WuXi AppTec. Building on the blue ocean market of infertility in reproductive health, CarrierGene is committed to using advanced genetic testing technology and data analysis algorithms to identify the causes of infertility for patients, facilitate follow-up treatment, and increase the birth rate of the population. CarrierGene is the driver and leader in the infertility field of China. CarrierGene has a GMP facility in Suzhou and an R&D and marketing center in Shanghai. Several products have already entered the clinical registration stage.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200106005345/en/

Follow this link:
NuProbe Global and CarrierGene Biotech Co. Ltd. Announced Completion of Merger, Appointed Yingshuang Chai as CEO, and Established Collaboration with...

Read More...

Father of preventive medicine, Dr Jeremiah Stamler, turns 100 – The Star Online

January 6th, 2020 4:42 pm

Dr Jeremiah Stamler has a little problem at work.

You know the kind: that checklist item that you cant quite seem to check, the one part of the big project that you havent yet nailed down.

You cant slam the door shut on the work until you get answers.

He knows the problem is out there, just waiting for him. And frankly, thats just the kind of thing he thrives on.

Dr Stamler is a professor emeritus and active researcher at the Northwestern University Feinberg School of Medicine in the United States, who recently turned 100 years old.

His problem is cheese.

Dr Stamlers speciality is preventive medicine in fact, he helped invent the field.

He did pioneering research into the causes of heart disease and coined the term risk factors to describe circumstantial and genetic contributors that increase the risk of cardiovascular disease.

While working for Chicagos Public Health Department in the 1960s, he developed the Heart Disease Control Program, aimed at educating the public and bringing focus to issues the city still grapples with, such as the availability of healthy food in poor neighbourhoods.

Hes an early adopter of whats known today as the Mediterranean diet and his own best advertisement, a long-living testament to the lifestyle changes he advocates.

Currently, hes one of only a tiny handful of scientists over age 90 to have an active US National Institutes of Health grant for research.

We have immense amounts of things we should be grateful to Dr Stamler for, says Dr Donald Lloyd-Jones, chair of Northwesterns Department of Preventive Medicine, because hes improved our health as a nation and a world, but hes also affected our society.

He points out that Dr Stamler, who founded the Department of Preventive Medicine, has retained 110% of his mental acuity. Hes forgotten more than I will ever know, and I dont think hes forgotten very much.

But aside from being an obvious outlier in the healthy-habits-plus-great-genes department, the record of Dr Stamlers life reveals another core characteristic that clearly fuels him.

Hes charming and smart, but he wont back down.

Not for anything. Not for big food companies or basic human intransigence, or even the US Congress. Not for the toll age takes, not even for time.

He has made standing up for things his stock-in-trade.

I think its a measure of his character, says Dr Lloyd-Jones. Its remarkable. Hes my hero.

A life in research

Dr Stamler was born in Brooklyn, New York, in 1919, and grew up in West Orange, New Jersey, the child of Russian immigrants.

From an early age, he was suspicious of mass-market food.

The loaf of white bread is anathema, he says. My father got to this country, saw the white bread and was ready to get back on the boat and go home!

Instead, he grew up with hearty rye breads and got an early start eating whole grains.

Other healthy habits came easy, he says: I never liked butter. I dont know why. It mustve been something in the blood intuitive.

After medical school, he did what most of his contemporaries were doing and entered the US Army.

Near the end of World War II, he was sent overseas. To Bermuda, he says. So I spent a lovely year in Bermuda, my wife came with me, and it was very nice.

Shortly thereafter, the war ended, and like thousands of other GIs, he headed home to launch the next phase of his life.

He knew he wanted that life to be in research, and in 1947, found a place to pursue that work, taking a position at Michael Reese Hospital in Bronzeville, Chicago, under pioneering cardiology researcher Dr Louis Katz.

Dr Katz told me, Why the hell do you want to go into research? says Dr Stamler.

You never win. When you first discover something, people will say I dont believe it.

Then you do more research and verify it, and theyll say, Yes, but...

Then you do more research, verify it further and theyll say, I knew it all the time.

And he was right.

Undeterred, Dr Stamler and his first wife Rose, who trained as a sociologist, but went on to become a major researcher in the fields of cardiovascular disease and hypertension in her own right, moved to Chicago in 1947.

They offered me a US$200-a-month fellowship, he says. In those days, that was a fortune.

His research involved examining the effects of cholesterol and other factors suspected as drivers of cardiovascular disease.

I was always interested in the heart artery problem. Why did human beings with diabetes get more heart artery disease?

Whats the relation of habitual lifestyle, fat intake, saturated fat intake, cholesterol intake, salt intake, with cardiovascular disease? The interplay between multiple factors.

And of course, we were all interested in tobacco even way back then.

He studied his theories on animals.

I was feeding cholesterol to chickens, he says. We could test everything that we suspected might have an impact, except smoking.

And over time, he helped discover and confirm many of the things we now take for granted: High cholesterol and high blood pressure are linked to cardiovascular disease.

Into public health

Dr Stamlers interest in these issues didnt stop at the merely scientific, however.

He had long been interested in social causes he and Rose had met at student meetings during World War II, while he was still in college, and her work leaned strongly into social justice.

He realised that his work had vast implications in the world outside the laboratory.

From 1948 on, as our work accelerated, he says, we were more inclined to translate our findings into recommendations for the public.

That approach began to earn him a few enemies.

Here in Chicago, we had the North American Meat Institute, they were barking at me all the time.

They had a very simple view: Why dont you do research, write papers, publish them and shut up?

We didnt feel that was an appropriate posture for people doing research on a scientific problem of great public health importance to do the research and then bury it. What the hell is the point?

Big tobacco, big food companies and other interest groups werent too happy about Dr Stamlers findings either.

He didnt care. I began to find the best ways to express all this to the public, and we decided that the best way is the risk factor concept, he says.

A set of well-defined traits, easily measured, frequently occurring, which when pre-sent, particularly in combination, are greatly associated with increased risk.

Risk factors, which represented something the public could understand and act to change, changed the face of how Americans thought about cardiovascular health.

The question was, what happens when you modify them, control them, lower them? Dr Stamler says.

Does the cigarette smoker at age 60, after more than 40 years of smoking, benefit from quitting smoking and lowering cholesterol?

The answer is, it isnt too late.

Dr Stamler was driven by a desire to see that knowledge put into practice by the public.

Its a very important message, he says. From a practical point of view, its the only message.

In 1958, he brought that activist approach to public health to city government, taking a position in Chicagos Department of Public Health.

I rolled up my sleeves and went formally to work, he says. A different kind of work. Quite different from feeding cholesterol to chickens.

Reluctantly, he gave up animal research and turned his attention to the pressing concerns of the citys health.

We started with rheumatic fever prevention in kids, he says.

We developed a hypertension control programme, coronary prevention evaluation programme, all right there in (then Chicago Mayor Richard J) Daleys Health Department.

He actually used a picture of me with one of the participants in the programmes in one of his political campaigns, to show how up-to-date and modern his administration was.

Dr Stamler also looked to tackle Chicagos diet: First and foremost, we worked to improve the mix of foods that were readily available in the supermarket.

We encouraged broiling rather than frying, roasting on a rotisserie rather than frying, modest portion sizes.

Chicagos legendary steakhouses? They didnt exactly fit Dr Stamlers programme.

It may be OK to victimise a tourist by selling him a 16-ounce (455g) steak, he says, but for the natives, lets make it a 4- or 5-ounce (113g or 142g) steak.

Lets encourage fish and seafood, vegetables and fruits, whole grains.

Not that were indifferent to the outside, but we feel a first responsibility to locals.

The question of the role cheese, as seen in this filepic, plays in heart disease is what currently occupies centenarian researcher Dr Stamlers thoughts.

An un-American accusation

But it wasnt steakhouses or even food lobbyists who posed Stamlers next challenge.

In 1965, he was called before the US House Un-American Activities Committee (HUAC), a congressional committee aimed at ferreting out suspected communist sympathisers in America.

The committee was known for subpoenaing a range of people, from the entertainment industry, academia and other spheres of public life.

They had informants who told them who to call, says Tom Sullivan, an attorney who worked on Dr Stamlers HUAC case, and the people took the Fifth Amendment (to the US Constitution, invoking a right against self-incrimination) and that was the end of it.

It ruined many lives and employment and wreaked havoc.

The consequences for refusing to answer the committees questions was blacklisting, and in Dr Stamlers case, Sullivan says, Mayor Daley would have fired him immediately.

Dr Stamler chose not to exercise a right against self-incrimination, instead choosing not to answer the committees questions to him by challenging its constitutional right to do so.

Sullivan and his team filed suit against the committee on behalf of Dr Stamler and his colleague Yolanda Hall, who worked as a nutritionist in his department and was also an outspoken activist on issues such as fair housing and civil rights.

The committee found the pair in contempt of the US Congress.

The clients were facing years in jail for contempt of Congress, says Sullivan, and Jerry Stamler decided he was willing to take that chance, to make this a test case.

Litigation followed for eight-and-half years, during which Dr Stamler continued to champion public health, but rarely spoke publicly about the court battle.

In late 1973, the case settled, with the committee, which had begun to lose steam, backing down and Dr Stamlers side agreeing to withdraw its complaint.

In 1975, HUAC was disbanded. The case, says Sullivan, was the decisive factor in ending it.

Those who know Dr Stamler best say the story isnt out of character.

He has a mantra, says Dr Lloyd-Jones, just apply firm, steady pressure.

When his scientific discoveries or medical recommendations meet resistance, Dr Lloyd-Jones says, his response is always the same: Keep smiling. But dont back down.

He knows that if you apply firm, steady pressure over time, the data will win the day.

If we make sure our assertions are grounded in the very best science, the truth will out.

Confronting cheese

In 1972, Dr Stamler was appointed as the founding director of the Department of Community Health and Preventive Medicine at Northwestern, where his research continued and he took on the role of mentor to a stream of new cardiologists and researchers.

The work has never let up, though Dr Stamler has decided where to draw the line in one arena.

He sort of stopped advancing in his tech use at fax machines, says Dr Lloyd-Jones, so when we send him papers to read, we email them to his assistant, they print them out, he takes the hard copy, he marks them up extensively in pen, and he faxes them back.

Currently, Dr Stamlers working with a team on metabolomics, the study of products created by the bodys metabolic processes.

Those faxed notes, Dr Lloyd-Jones says, are sharp as ever.

Hes really at his core a scientist. Hes always about taking the data and what it is giving you, and not over-interpreting it.

Dr Stamler sticks to his guns at home as well.

Read the original post:
Father of preventive medicine, Dr Jeremiah Stamler, turns 100 - The Star Online

Read More...

Experts Come Together to Save 3-year-old Gorilla’s Eyesight at San Diego Zoo Safari Park – UC San Diego Health

January 6th, 2020 4:42 pm

A 3-year-old western lowland gorilla named Leslie at the San Diego Zoo Safari Park developed a traumatic cataract. After a UC San Diego Health surgeon successfully removed the cataract, Leslie returned to her playful antics alongside the rest of the Safari Park troop. Photo by San Diego Zoo Global

Animal care specialists at the San Diego Zoo Safari Park were concerned when they noticed cloudiness in the left eye of Leslie, a 3-year-old female western lowland gorilla. Closer inspection confirmed the lens had changed and the left eye was shifting haphazardly, prompting Leslie to favor use of her right eye.

Given Leslies young age and developmental stage, Safari Park veterinarians organized a team of internal and external experts, including ophthalmologists and anesthesiologists at UC San Diego Health, to perform the Parks first-ever cataract surgery on a gorilla.

As veterinarians, we are experts in our species but we are not necessarily specialists in all of the different fields of medicine, said Meredith Clancy, DVM, San Diego Zoo Safari Park associate veterinarian. We rely heavily on the amazing community we have here in San Diego to help us out.

On December 10, 2019, surrounded by animal care experts and veterinarians in khaki uniforms and UC San Diego Health medical team members in scrubs, Leslie rested comfortably in the operating room at the San Diego Zoo Globals Paul Harter Veterinary Medical Center. A pharmaceutical muscle blocker prevented even the slightest of movement, allowing Chris W. Heichel, MD, cataract surgery specialist at Shiley Eye Institute at UC San Diego Health, to perform the delicate procedure.

Heichel and his team employed a specialized microscope and instruments designed for cataract surgery to successfully remove the cataract in Leslies left eye using gentle suction. Once the cloudy lens was removed, a new artificial lens was inserted, which is designed to provide Leslie with clear vision for the rest of her life.

Chris W. Heichel, MD, cataract surgery specialist at Shiley Eye Institute at UC San Diego Health, and his team employed a specialized microscope and instruments designed for cataract surgery to successfully extract a cataract in the left of 3-year-old gorilla at the San Diego Zoo Safari Park. Photo by Ken Bohn, San Diego Zoo Global

While Heichel has performed thousands of eye surgeries on human patients, ranging in age from one day to 105 years, this was his first surgery on a gorilla.

Fortunately, the similarities between the anatomy of human and gorilla eyes are great enough to allow us to safely navigate the procedure without complication, said Heichel. The remainder of the eye appeared to be in excellent health, indicating exceptional vision potential for the rest of Leslies life.

A cataract is a clouding of the clear lens behind the colored part of the eye, known as the iris. Cataracts typically develop over time, as part of the normal aging process, but they can also be caused by trauma to the eye. Once a cataract develops, the lens becomes progressively cloudier and vision deteriorates.

Heichel, Clancy and animal caregivers suspect that Leslies cataract was a result of an injury, either from a fall while the youngster was practicing her climbing skills or from an overly rambunctious play session with other young gorillas in her troop.

As she recovers, Leslie will require both topical and oral antibiotics and steroids to prevent infection and to control postoperative inflammation, said Clancy. Leslie will be monitored closely, but she is already back with her troop in the Gorilla Forest habitat at the Safari Park.

Following successful healing, the remaining concern is the possibility of cloudiness recurring.

The eye has an envelope that holds the lens in place. It should remain clear, but sometimes after cataract surgery, the envelope will get a little cloudy, said Heichel, professor of ophthalmology in the Viterbi Family Department of Ophthalmology at UC San Diego School of Medicine. In a human patient, we can laser the envelope to remove the cloudiness. That might not be quite so easy for Leslie, therefore I made a little opening in the back of the envelope to maintain her clear vision in the future. I am grateful for the chance I had to work with the exceptional San Diego Zoo Global team to help have a positive impact on Leslies life.

Because of Leslies age, the Safari Parks animal care team was concerned her 31-year-old mother, Kokamo, might be upset about Leslies absence from the gorilla habitat during the procedure. They elected to anesthetize Leslie and Kokamo at the same time, and use the opportunity to perform a routine health check on Kokamo, which included dental, cardiac and overall physical assessments. The results of Kokamos exam showed that she continues to be in good health.

About San Diego Zoo GlobalAs an international non-profit organization, San Diego Zoo Global works to fight extinction through conservation efforts for plants and animals worldwide. With a history of leadership in species recovery and animal care, San Diego Zoo Global works with partners in science-based field programs on six continents, and maintains sanctuaries and public education facilities in many places. Inspiring passion for nature is critical to saving species, and San Diego Zoo Globals outreach efforts share the wonder of wildlife with millions of people every year. Current major conservation initiatives include: fighting wildlife trafficking and the impacts of climate change on wildlife species; broad-spectrum species and habitat protection efforts in Kenya, in Peru and on islands worldwide; preventing extinction in our own backyard; and expanding efforts to bank critical genetic resources and apply them to the conservation of critically endangered species. To learn more, visit sandiegozooglobal.org or connect with us on Facebook.

About UC San Diego HealthUC San Diego Health, the regions only academic health system, is dedicated to delivering outstanding patient care through commitment to community, groundbreaking research and inspired teaching. For 2019-20, U.S. News & World Report ranked UC San Diego Health among the nations best in four adult medical and surgical specialties, including pulmonology, geriatrics, neurology and cardiology. The 808-bed academic health system includes UC San Diego Medical Center in Hillcrest and Jacobs Medical Center, Sulpizio Cardiovascular Center, Moores Cancer Center, Shiley Eye Institute, Koman Family Outpatient Pavilion and Altman Clinical and Translational Research Institute, all in La Jolla, as well as primary care and same-day services at clinics throughout Southern California. For more information, visit health.ucsd.edu.

Go here to see the original:
Experts Come Together to Save 3-year-old Gorilla's Eyesight at San Diego Zoo Safari Park - UC San Diego Health

Read More...

Atrium Innovations to Further Scale the Future of Personalized Nutrition with the Acquisition of LivingMatrix – BioSpace

January 5th, 2020 8:45 am

Atrium Innovations, a Nestl Health Science company, to leverage clinician-designed, algorithm-driven platform with healthcare providers

SUDBURY, Mass., Jan. 3, 2020 /PRNewswire/ -- Atrium Innovations, a globally-recognized leader in the development, manufacturing, and commercialization of innovative, science-based nutritional health products, takes the next step in the company's mission to expand into personalized nutrition with the acquisition of San Francisco-based LivingMatrix. LivingMatrix, a technology-based, data and algorithm-driven personalized functional medicine platform, was designed by clinicians to help practitioners effectively evaluate and engage patients, create personalized, actionable care plans and track patient health outcomes.

"This exciting acquisition is reflective of the current mission and direction for Atrium Innovations, with support from Nestl Health Science, to expand our role in personalization within the medical professional and consumer spaces. The addition of LivingMatrix will allow us to take the next steps in leading the future of personalized health management," says Kyle Bliffert, President of Atrium Innovations. "Our goal is to further scale our personalization platform through integrating LivingMatrix with our existing PureGenomics platform and future healthcare provider patient management systems providing the most comprehensive solution in the industry."

"The addition of LivingMatrix to the Atrium Innovations growing personalized medicine portfolio will further elevate the way functional medicine practitioners and patients in our longstanding network view and use healthcare," adds Joy Devins, Chief Strategic Leader of Atrium Innovations.

"The launch of the LivingMatrix platform has been a critical turning point for personalized and functional medicine and now, with the support of the Atrium Innovations and Nestl Health Science family, we look forward to breaking even more barriers," says Priya Kamani, Founder and CEO of LivingMatrix. "This partnership brings opportunities to scale the business and accelerate our ability to drive and support additional research studies to expand the evidence base for effectively addressing chronic conditions."

LivingMatrix is the latest acquisition for Nestl Health Science as part of the company's mission to lead the personalized nutrition sector into its next evolution. Their recent acquisition of Persona, a science-based proprietary technology which considers specific factors in a consumer's lifestyle, history and individual needs to develop a personalized vitamin program, was announced in August 2019. Persona's individualized assessments meet consumers' desires to find the right nutritional supplements for their unique needs. These personalized vitamin and supplement services are available to consumers through http://www.personanutrition.com. These strategic acquisitions will leverage Atrium Innovations' nearly 30-year industry expertise, bringing valuable insight from the company's network of medical professionals as well as professional brand development knowledge to the partnership.

"Through combining the strength of Persona's proprietary algorithm, the LivingMatrix data-driven technology and Atrium Innovation's leadership in the industry, we are creating an exciting future for personalized nutrition for professionals and consumers alike," says Bliffert.

For more information about Atrium Innovations, visit http://www.atrium-innovations.com.

About Nestl Health Science (NHSc)Nestl Health Science (NHSc), a wholly-owned subsidiary of Nestl, is a globally recognized leader in the field of nutritional science. NHSc is committed to empowering healthier lives through nutrition for consumers, patients and their healthcare partners. The company offers an extensive consumer health portfolio of industry-leading medical nutrition, consumer and VMS brands that are science-based solutions covering all facets of health from prevention, to maintenance, all the way through to treatment. NHSc is redefining the approach to their management of health in several key areas such as pediatric health, allergy, acute care, oncology, metabolic health, healthy aging, gastrointestinal health, and inborn errors of metabolism. Headquartered in Switzerland, NHSc employs over 5,000 people around the world, who are committed to making a difference in people's lives, for a healthier today and tomorrow. For more information, visit https://www.nestlehealthscience.com.

About Atrium Innovations Atrium Innovations is a recognized innovative leader in the development, manufacturing, and commercialization of science-based nutritional and supplement health products. The company's mission is to be a global leader in vitamins, minerals and supplements, offering free form science based nutritional solutions through healthcare professionals. Its brands and business model are complementary with Nestl Health Science, its parent company, offering science-based nutritional solutions for consumers, patients, doctors, nurses and other partners in healthcare. Atrium Innovations Professional brands include Pure Encapsulations, Douglas Laboratories, Genestra BrandsTM, KLEAN Athlete, PharmaxTM, and Wobenzym.

About LivingMatrixLivingMatrix is the leading cloud-based, clinician-designed, outcomes-focused personalized medicine platform, helping over 600 practices in 22 countries engage in high-quality, personalized, therapeutic partnerships to address chronic conditions at scale effectively. LivingMatrix has partnered with the Institute for Functional Medicine and helps practitioners deliver a unique engagement process utilizing the Timeline and Matrix tools, and validated, patient-reported outcomes measures that provide a comprehensive assessment of a patient's health and objective tracking of patient progress. The result is a faster time to life-changing outcomes for the patient and an increase in referrals and growth for the practice. Learn more at https://livingmatrix.com

About Persona Persona combines therapeutic levels of nutritional support and a uniquely personalized vitamin program to deliver customized nutrition to subscriber's doorsteps. Based on science and using the highest-quality bioavailable ingredients, Persona's online assessment is built from its proprietary algorithm, which factors individual needs, lifestyle and prescription medications to deliver a recommendation as unique as the patient providing 5 trillion different recommendations. https://www.personanutrition.com Instagram:@personanutrition

Media Contact:Ashley HughesRLA Collective, a Ruder Finn Company(914) 241-0086, ext. 1014Ashley.Hughes@RLACollective.com

View original content to download multimedia:http://www.prnewswire.com/news-releases/atrium-innovations-to-further-scale-the-future-of-personalized-nutrition-with-the-acquisition-of-livingmatrix-300980716.html

SOURCE Atrium Innovations

See the article here:
Atrium Innovations to Further Scale the Future of Personalized Nutrition with the Acquisition of LivingMatrix - BioSpace

Read More...

Cardio Round-up: Look Back at 2019, The Importance of Sleep, and More – DocWire News

January 5th, 2020 8:45 am

This weeks Cardio Round-up features a look back at what you may have missed during the holidays, as well as some of the big 2019 cardiology stories.

The past year saw some big stories like the Apple Heart study, presented at ACC.19, which essentially validated the ability of a wearable device (an Apple iWatch) equipped with a tachogram-tracking algorithm was able to detect pulse irregularities associated with atrial fibrillation. Icosapent ethyl also featured prominently, gaining an FDA approval for the reduction of cardiovascular disease risk as an add-on to statin therapy in high-risk patients with hypertriglyceridemia. Dapagliflozin (highlighted in the DAPA-HF study) also was shown to be an effective treatment for heart failure in both diabetic and non-diabetic patients.

2019 In Cardiology: Apple Heart Study Lands; Icosapent Ethyl Gets FDA Nod for New Indication; Dapagliflozin For Nondiabetics; and More

A new observational study published inEuropacesuggests it is possible to monitor and predict individual progression ofatrial fibrillation (AFib) using pacemakers or defibrillators.We aimed to study the progression of AER in individual patients with implantable devices and AFib episodes, the paper authors wrote. The study results indicated that the slope of AAR changes during the progression of AFib showed patient-specific patterns correlating with the time-to-completion of AER (R2 = 0.85). This technology opens up enormous possibilities in personalized medicine for AFib patients because it allows us to determine the progression rate of the arrhythmia in each individual and to optimize the timing of medical intervention with current treatment options, one of the researchers said in a press release.

Personalized Medicine for AFib: How Electric Activity in the Heart Can Predict Individual Progression of Atrial Fibrillation

A research team, publishing the study in the Journal of Molecular and Cellular Cardiology, worked on converting adipogenic mesenchymal stem cells, which reside within fat cells, into cardiac progenitor cells. The ensuing cardiac progenitor cells can be programmed to aid heartbeats as a sinoatrial node (SAN), which is part of the electrical cardiac conduction system.We are reprogramming the cardiac progenitor cell and guiding it to become a conducting cell of the heart to conduct electrical current, said study co-author Bradley McConnell, associate professor of pharmacology, in a press release. Results of this study show that the SHT5 combination of transcription factors can reprogram CPCs into Pacemaker-like cells.

The Next Generation of Biologic Pacemakers? New Discovery in Stem Cells from Fat Creates Another Alternative Treatment

Diabetes mellitus is an independent predictor for heart failure, according to the findings of a study published inMayo Clinic Proceedings. In this study, using the Rochester Epidemiology Project, researchers assessed the long-term impact ofdiabeteson the development of heart failure by including 116 study subjects with diabetes, who were matched 1:2 based on age, hypertension, sex, coronary artery disease and diastolic with 232 participants without diabetes. The results showed that that diabetes is an independent risk factor for the development of heart failure. Over the duration of 10 years, 21% of participants with diabetes developed heart failure, independent of other causes. The researchers observed that by comparison, only 12% of patients without diabetes developed heart failure. The key takeaway is that diabetes mellitus alone is an independent risk factor for the development of heart failure, wrote one of the authors.

Diabetes is an Independent Predictor for Heart Failure

A new study suggests that regularly getting a good nights sleep isnt just a helpful overall health recommendation but is also an essential way to keep risk for heart disease and stroke down. The paper, published in theEuropean Journal of Cardiology, included more than 300,000 participants initially free of cardiovascular disease (CVD) from UK Biobank. According to the results, there were 7,280 documented cases of incident CVD (4,667 coronary heart disease and 2,650 stroke) cases. Participants with a sleep score of 5 had a 35% reduced risk for CVD, a 34% reduced risk for coronary heart disease, and a 34% reduced risk for stroke when compared to participants with a score of 0-1.As with other findings from observational studies, our results indicate an association, not a causal relation, one of the authors said in a press release. However, these findings may motivate other investigations and, at least, suggest that it is essential to consider overall sleep behaviors when considering a persons risk of heart disease or stroke.

Getting Quality Sleep, and the Right Amount, Can Offset Genetic Susceptibility for Heart Disease and Stroke Risk

See the original post:
Cardio Round-up: Look Back at 2019, The Importance of Sleep, and More - DocWire News

Read More...

Iowa City doctor seeking more time with patients opens ‘concierge’ practice – The Gazette: Eastern Iowa Breaking News and Headlines

January 5th, 2020 8:45 am

IOWA CITY Throughout his 29 years as an internal medicine doctor in Iowa City, Dr. Richard Larew felt the pressure building.

There were demands to see more patients, meaning he couldnt spend as much time with each patient as he wished.

I was trying to find a way to get back to the way we have done things in the past, Larew said. There was more time. There wasnt quite the same pressure to see so many people.

Larew left hospital practice earlier this year to go into private practice and open Larew Internal Medicine, at 2557 N. Dodge St. in Iowa City.

Hes using an alternative care model called concierge medicine that allows him more time with fewer patients for a fee.

In exchange for an annual retainer, Larew limits his patient count, allowing him time for extended visits and agreeing to be available to patients at any time for any medical concern.

Larew has about 200 patients on his retainer. Each patient pays about $1,800 a year for the service, or $150 a month.

Larew, who grew up in Iowa City, had worked for Mercy Iowa Citys Towncrest Internal Medicine for 29 years before opening his concierge practice in July.

ARTICLE CONTINUES BELOW ADVERTISEMENT

Larews patients are able to get same-day appointments for acute illnesses, such as influenza, and they have Larews cellphone number for questions they might have after hours.

The majority of Larews patients are those with multiple chronic medical conditions, such as diabetes and high blood pressure, who he sees every three months. He refers such patients to specialists and tracks their progress.

Thats not a model theyre accustomed to using, Larew said. They just come in when theyre sick. The idea that we would spend a good part of time (during the visit) talking about how they can improve things is a different way of thinking about it.

Through concierge agreements, Larew believes he is able to provide more comprehensive, proactive care to patients.

He also thinks the agreements give patients a chance to reconnect with their primary care physician.

Part of what has always made medicine and being a physician a great profession is that personal connection, he said.

Kathy McCue, 66, of Iowa City, signed up for Larews medical concierge service when it opened. Larew had been her doctor for at least 20 years, and she wanted to stay with him.

I dont have any big health concerns, but if something did come up, I would like him to be my point person to be able to talk through things, McCue said.

McCue described Larew as thorough, a good listener and someone who loves educating patients and answering their questions.

ARTICLE CONTINUES BELOW ADVERTISEMENT

I think thats why he transitioned to concierge medicine, she said. He loves that part in medicine, and I always said he would be a good professor in that way.

And, its nice to have as a patient.

Concierge medicine, sometimes known as membership medicine, was created in the late 1990s by two Seattle physicians who wanted to offer more personalized medicine.

Concierge Medicine Today, a trade publication, estimated 5,000 to 6,000 doctors were practicing concierge medicine in 2018, though no database tracks the numbers. The approach inspired a USA Network television series, Royal Pains.

The method comes in for criticism because its available only to those who can afford the monthly fee, on top of their regular health insurance premiums.

A 2016 study published by the Population Health Management journal found patients health care expenditures declined in the third year of participation in concierge medicine programs. Researchers suggested that happens because patients address untreated health concerns and are caught up with chronic disease management.

Not much other research exists on the concept.

No one knows how to measure whos getting healthier, but do I think that people are benefiting? Absolutely, Larew said.

I think were achieving what were hoping to, he said. I want people to have a great experience when they walk in the door, and I want to be able to provide people with that extra time.

Comments: (319) 368-8536; michaela.ramm@thegazette.com

Read the original post:
Iowa City doctor seeking more time with patients opens 'concierge' practice - The Gazette: Eastern Iowa Breaking News and Headlines

Read More...

MANDEL: Divorced Toronto dad pushes ahead in vaccination fight – Toronto Sun

January 5th, 2020 8:44 am

A divorced Toronto dad has just won a slim victory in his ongoing battle with his ex-wife over her refusal to vaccinate their two children.

The father, who can only be identified as A.P. under a court-ordered publication ban, was recently given the go-ahead by the court to have bona fide vaccination experts testify on his behalf in his appeal of a shocking 2018 family law arbitration decision that sided with anti-vaxxers who falsely claim vaccines do more harm than good.

Its great news, says the dad. The judge recognized that the arbitrator made his decision without experts on my side.

Arbitrator Herschel Fogelman accepted the evidence of Dr. Toni Bark, despite the Chicago-based medical doctor having been rejected as an expert vaccination witness in a recent case in the United States.

Choosing not to vaccinate is not illegal, negligent nor immoral. It is a personal choice, wrote Fogelman in his controversial decision. I am unable to find any risk to (the children) if they remain unvaccinated. Further, I am satisfied on the evidence the vaccines may pose additional risk to them.

Self-represented at the time, the dad tried to introduce his own expert report from Dr. Alana Rosenthal, a specialist in pediatric infectious diseases and consultant in infectious diseases at Sick Kids and North York General Hospital. She concluded that no scientific studies have shown vaccinesto be harmful.

But the arbitrator said Rosenthal would have had to testify in person and despite the father`s offer to contact her he refused to accept her evidence.

The dad not only lost his bid to have his kids vaccinated they are now 13 and nine but was ordered to pay $35,000 in the moms legal costs, which included the $11,000 she paid Bark.

After his story went public in the National Post, his Gofundme campaign raised more than $14,000 toward his hiring a legal team to launch an appeal. He was also overwhelmed with support from the health community with offers to testify on his behalf at no cost.

Last month, the Ontario Superior Court agreed the dad can introduce fresh evidence from three renowned experts when his appeal is heard in March.

The doctors credentials are lengthy and impressive and put Barks thin resume to shame. In addition to Rosenthal, he has Dr. Lawrence Loh, Peels associate medical officer of health who served as senior medical consultant in the vaccine safety section at the Public Health Agency of Canada; and Dr. Neal Sondheimer, staff physician in metabolic genetics at the Hospital for Sick Children and an associate professor of pediatrics in molecular genetics at UofT.

Justice Jasmine T. Akbarali, though, rejected the dads fresh evidence challenging Barks credentials or his bald allegation that Dr. Bark is a hired gun, takings tens of thousands of dollars to testify against the use ofvaccinations.

More worrying to the father was the judges decision to accept the new evidence from their childrens pediatrician: Her greatest and only concern at this point in time is for the psychological and emotional health of the children in view of the high-conflict divorce, and the media attention this case has attracted, Akbarali noted.

While the pediatrician recommends vaccinations to all her patients, she wrote that she believes the 13-year-old is mature enough to decide for himself and has expressed the wish not to be administered any vaccinations at the present time.

Is a doctor really recommending that a 13-year-old child should be able to decide if he wants to be vaccinated?

I was blown away, the father says.

I`m trying to be optimistic. But what may happen is that my oldest will be allowed to make his own decision. Thats the worst case where he is forced to choose between his moms side or his dads side. Its a lot of pressure for a 13-year-old.

And in the meantime? Both children contracted a bout of whooping cough they never had to suffer.

mmandel@postmedia.com

Originally posted here:
MANDEL: Divorced Toronto dad pushes ahead in vaccination fight - Toronto Sun

Read More...

Gut communication with body restricted by consumption of fatty foods: Study – ANI News

January 5th, 2020 8:44 am

ANI | Updated: Jan 04, 2020 17:51 IST

Washington D.C. [USA], Jan 4 (ANI): Fast food attracts people due to its easy accessibility and inexpensiveness, but these easily available food options are loaded with oil, grease and saturated fats, which affects the human health.A recent study has suggested that food items containing more grease and fat can put the communication between intestine and the rest of the human body to stop.A team of Duke researchers has discovered that a high-fat meal completely shuts down the communication for a few hours. After they observed using the fish to examine cells that normally tell the brain and the rest of the body what's going on inside the gut after a meal.The cells they were looking at are the enteroendocrine cells, which occur sparsely throughout the lining of the gut, but play a key role in signalling the body about the all-important alimentary canal. In addition to releasing hormones, the cells also have a recently-discovered direct connection to the nervous system and the brain.These cells produce at least 15 different hormones to send signals to the rest of the body about gut movement, feelings of fullness, digestion, nutrient absorption, insulin sensitivity, and energy storage."But they fall asleep on the job for a few hours after a high-fat meal, and we don't yet know if that's good or bad," said John Rawls, an associate professor of molecular genetics and microbiology in the Duke School of Medicine.Since enteroendocrine cells are key player's indigestion, the feeling of being full and subsequent feeding behaviour, this silencing may be a mechanism that somehow causes people eating a high-fat diet to eat even more."This is a previously unappreciated part of the postprandial (after-meal) cycle," Rawls said."If this happens every time we eat an unhealthy, high-fat meal, it might cause a change in insulin signalling, which could, in turn, contribute to the development of insulin resistance and Type 2 diabetes."To understand the silencing better, the researchers tried to break the process down step by step in zebra-fish, reports the study published in 'eLife'.After they first sense a meal, the enteroendocrine cells trigger a calcium burst within seconds, initiating the signalling process.But after that initial signal, there's a delayed effect later in the after-meal period. It's during this later response that the silencing occurs, said Rawls, who also directs Duke's Microbiome Center.The silenced cells change shape and experience stress in their endoplasmic reticulum, a structure that assembles new proteins. It seems that these enteroendocrine cells, which are specialised to synthesise and secrete proteins like hormones and neurotransmitters, become overstimulated and exhausted for a while.The team tried the high-fat diet on a line of germ-free zebrafish raised in the absence of any microbes and found they didn't experience the same silencing effect. So they began looking for gut microbes that might be involved in the process.After screening through all the kinds of bacteria found in the gut, they saw that the silencing appeared to be the work of a single type of gut bacteria, called Acinetobacter. (ANI)

Read the original here:
Gut communication with body restricted by consumption of fatty foods: Study - ANI News

Read More...

Gene editing breakthroughs that cured genetic diseases in 2019 – The Star Online

January 5th, 2020 8:44 am

IN the summer of 2019, a mother in Nashville, Tennessee in the United States, with a seemingly incurable genetic disorder finally found an end to her suffering by editing her genome.

Victoria Grays recovery from sickle cell disease, which had caused her painful seizures, came in a year of breakthroughs in one of the hottest areas of medical research gene therapy.

I have hoped for a cure since I was about 11, the 34-year-old said.

Since I received the new cells, I have been able to enjoy more time with my family without worrying about pain or an out-of-the-blue emergency.

Over several weeks, Grays blood was drawn so that doctors could get to the cause of her illness stem cells from her bone marrow that were making deformed red blood cells.

The stem cells were sent to a Scottish laboratory, where their DNA was modified using Crispr/Cas9 pronounced Crisper a new tool informally known as a molecular scissors.

The genetically-edited cells were transfused back into Grays veins and bone marrow. A month later, she was producing normal blood cells.

Medics warn that caution is necessary, but theoretically, she has been cured.

This is one patient. This is early results. We need to see how it works out in other patients, said her doctor, Haydar Frangoul, at the Sarah Cannon Research Institute in Nashville.

But these results are really exciting.

In Germany, a 19-year-old woman was treated with a similar method for a different blood disease beta thalassemia.

She had previously needed 16 blood transfusions per year. Nine months later, she is completely free of that burden.

For decades, the DNA of living organisms such as corn and salmon has been modified. But Crispr, invented in 2012, made gene editing more widely accessible.

It is much simpler than preceding technology, cheaper and easy to use in small labs.

The technique has given new impetus to the perennial debate over the wisdom of humanity manipulating life itself.

Its all developing very quickly, said French geneticist Emmanuelle Charpentier, one of Crisprs inventors and the co-founder of Crispr Therapeutics, the biotech company conducting the clinical trials involving Gray and the German patient.

Gene cures

Crispr was the latest breakthrough in a year of great strides in gene therapy, a medical adventure that started three decades ago, when the first TV telethons were raising money for children with muscular dystrophy.

Scientists practising the technique insert a normal gene into cells containing a defective gene.

It does the work the original could not, such as making normal red blood cells in Grays case or making tumour-killing super white blood cells for a cancer patient.

Crispr goes even further: instead of adding a gene, the tool edits the genome itself.

After decades of research and clinical trials on a genetic fix to genetic disorders, 2019 saw a historic milestone: approval to bring to market the first gene therapies for a neuromuscular disease in the US and a blood disease in the European Union.

They join several other gene therapies bringing the total to eight approved in recent years to treat certain cancers and an inherited blindness.

Serge Braun, the scientific director of the French Muscular Dystrophy Association, sees 2019 as a turning point that will lead to a medical revolution.

Twenty-five, 30 years, thats the time it had to take, he said. It took a generation for gene therapy to become a reality. Now, its only going to go faster.

Just outside Washington, at the US National Institutes of Health (NIH), researchers are also celebrating a breakthrough period.

We have hit an inflection point, said US NIHs associate director for science policy Carrie Wolinetz.

These therapies are exorbitantly expensive, however, costing up to US$2 million (RM8.18 million) meaning patients face grueling negotiations with their insurance companies.

They also involve a complex regimen of procedures that are only available in wealthy countries.

Gray spent months in hospital getting blood drawn, undergoing chemotherapy, having edited stem cells reintroduced via transfusion and fighting a general infection.

You cannot do this in a community hospital close to home, said her doctor.

However, the number of approved gene therapies will increase to about 40 by 2022, according to Massachusetts Institute of Technology (MIT) researchers.

They will mostly target cancers and diseases that affect muscles, the eyes and the nervous system.

In this Oct 10, 2018, photo, He speaks during an interview at his laboratory in Shenzhen, China. The scientist was recently sentenced to three years in prison for practicing medicine illegally and fined 3 million yuan (RM1.76 million). AP

Bioterrorism potential

Another problem with Crispr is that its relative simplicity has triggered the imaginations of rogue practitioners who dont necessarily share the medical ethics of Western medicine.

In 2018 in China, scientist He Jiankui triggered an international scandal and his excommunication from the scientific community when he used Crispr to create what he called the first gene-edited humans.

The biophysicist said he had altered the DNA (deoxyribonucleic acid) of human embryos that became twin girls Lulu and Nana.

His goal was to create a mutation that would prevent the girls from contracting HIV (human immunodeficiency virus), even though there was no specific reason to put them through the process.

That technology is not safe, said Kiran Musunuru, a genetics professor at the University of Pennsylvania, explaining that the Crispr scissors often cut next to the targeted gene, causing unexpected mutations.

Its very easy to do if you dont care about the consequences, he added.

Despite the ethical pitfalls, restraint seems mainly to have prevailed so far.

The community is keeping a close eye on Russia, where biologist Denis Rebrikov has said he wants to use Crispr to help deaf parents have children without the disability.

There is also the temptation to genetically edit entire animal species, e.g. malaria-causing mosquitoes in Burkina Faso or mice hosting ticks that carry Lyme disease in the US.

The researchers in charge of those projects are advancing carefully however, fully aware of the unpredictability of chain reactions on the ecosystem.

Charpentier doesnt believe in the more dystopian scenarios predicted for gene therapy, including American biohackers injecting themselves with Crispr technology bought online.

Not everyone is a biologist or scientist, she said.

And the possibility of military hijacking to create soldier-killing viruses or bacteria that would ravage enemies crops?

Charpentier thinks that technology generally tends to be used for the better.

Im a bacteriologist -- weve been talking about bioterrorism for years, she said. Nothing has ever happened. AFP Relaxnews

We're sorry, this article is unavailable at the moment. If you wish to read this article, kindly contact our Customer Service team at 1-300-88-7827. Thank you for your patience - we're bringing you a new and improved experience soon!

Article type: metered

User Type: anonymous web

User Status:

Campaign ID: 7

Cxense type: free

User access status: 3

Follow this link:
Gene editing breakthroughs that cured genetic diseases in 2019 - The Star Online

Read More...

COMMENTARY: Obsessed with Trump, our blindness to urgent issues grows – New Jersey Hills

January 5th, 2020 8:42 am

Like many Americans, I was shocked that our president ran what amounts to a transnational mafia in bed with Russian and Ukrainian oligarchs who benefit from Russian President Vladimir Putins war for totalitarian control of Ukraine against a free people who have struggled and suffered so much for their freedom.

We might be even more shocked if we had the transcript of Trumps call with Recep Tayyip Erdogan, president of Turkey and friend of Putin, which led to our betrayal of the Kurdish allies who did most of the hard ground fighting against ISIS for us. The ethnic cleansing of Kurds out of northern Syria is a crime against humanity and should have been included in the articles of impeachment.

But while we are focused on the vileness of Rudolph Guiliani and other mobsters, experts and pundits discussing these events completely ignore the massive, glaring questions of how to prevent such things from happening again. Even impeachment and conviction in the Senate, which will never happen, would not solve problems far bigger than Donald Trumps serious abuses of powers.

We need amendments to protect the professional civil service (especially in law enforcement and foreign affairs), to counter corruption in the federal government (e.g. by requiring tax-return disclosure), to clarify grounds for impeachment, and to limit pardon powers. It is staggering that even these problems so directly linked with current controversies never come up in mainstream coverage.

And this is only the beginning: We all really need to stop focusing solely on this impeachment, despite the cowardly way many Republicans are trying to defend Trump with conspiracy-spins drawn directly from Russian propaganda.

To solve the roots of this polarization that is making too many Americans on the political extremes prefer ideology to reality, we need constitutional change to end the dominance of two major parties with automatic runoffs, to rotate primaries between all states so Iowa and New Hampshire no longer go first every time, to prevent gerrymandering and dark money in our elections, to establish uniform national voting and count procedures, set Supreme Court terms and ban the filibuster in Congress. It is colossal collective folly that we focus only on the symptoms while ignoring the root problems that prevent fair elections and perpetuate endless gridlock in D.C.

Even before the Ukraine news broke, we were largely ignoring many other urgent issues that will have much profounder effects on our children and grandchildren. Climate change gets deserved attention, but there are several other dangers that, taken together, could harm human prospects even more than climate change, although they get virtually no attention in this country.

The regime in China, which now holds more than a million of its people in concentration camps in a genocidal effort to erase an entire minority culture, is creating a nightmare of totalitarian control a hundred times worse than anything Orwell ever imagined. At home, its facial-recognition cameras are everywhere and all its people will be increasingly monitored via data collection.

China also is pressuring many other countries in Asia and Africa to obey its commands, and the strong-arm tactics we have seen used against the NBA and Asian journalists are only the tip of the iceberg. It will not help our grandchildren much to be saved from climate change only to live as slaves under a global tyranny run from Beijing and Moscow.

Yet, almost no Americans understand that we are going to wake up in a couple years to discover that China has invaded Taiwan and that NATO will not do anything to stop it because we want the money from trade.

Similarly, because of the gridlock in D.C. caused by constitutional flaws, you may wake up one day a decade from now to discover that the American government is defaulting on a federal debt that maybe exceeds $50 trillion ($50,000 billion) in 15 years or less, sending the world into a new Great Depression which finally cements Chinas dominance in the aftermath.

That is, if loose nukes getting to terrorists or pandemic diseases originating in the worlds poorest nations or cybercrime viruses running rampant do not take us into economic armageddon first. Remember this as Democrats and Republicans promote the new brand of moronic isolationism rather than seeking new arrangements to share essential tasks effectively among our allies.

This staggering collective blindness is a result of the deepest flaw of all in our social system: In the 20th century, as television and radio appeared, we were content to allow mass media to be delivered on a for-profit basis. For a long time, editors and producers felt responsible to cover stories that people needed to hear because of their objective importance, whether they grabbed high ratings or not.

Today, that ethic is so completely gone that CNN, which I have watched since it was founded, covers almost no global news at all. In fact, for more than four years, it has covered almost nothing but American federal politics.

Fox also has focused almost solely on American federal politics, with a few other cherry-picked stories to appeal to its base like an occasional immigrant committing some crime or some stupid campus activists trying to no-platform a right-wing speaker. Their international coverage is limited to things that might seem to boost Trump, such as a happy Turkish general proclaiming the safe zone in northern Syria that is, a zone made safe from Kurds in the same way that the Trail of Tears made eastern states safe from the Cherokee. This propaganda machine heavily influences the nation now.

More broadly, internet medias focus entirely and solely on what is trending or popular with its group of viewers, which will include few events beyond our shores. Most Americans never see a major newspaper with fact-checked journalism; they finish high school without learning about current world affairs or even the basics of American civics, such as key numbers for parts of the federal budget or the history of main tax rates, the federal deficit, projections for Medicare, etc. let alone elementary critical thinking that would enable them to distinguish reliable sources from total crap.

Combined, these problems mean the death of democracy through completely manipulable voters. Both could be fixed by fairly simple constitutional reforms to improve our mass medias and education requirements.

The stupidity resulting from only-trendy media is so colossal today that even domestic issues that are massively in our face everywhere get only the most superficial analysis. Federal anti-monopoly laws have not been seriously updated in almost 100 years, and yet we wonder how Amazon, Microsoft, Google and Facebook can own more and more parts of supply chains, buy up all competitors and abuse power in service of profit.

When a small handful of corporations own most of the systems on which our lives totally depend, sell all our private information to insurance companies and marketers, and crush any dissenting opinion with their ability to manipulate what people view, it will be much harder to unwind this plutocracy. Yet it never even occurs to us to discuss the smallest countermeasures, like EU-style laws protecting data privacy.

Of course, this will not matter much if Google has unleashed a smart Artificial Intelligence system that does more damage than climate change. Or if genetic engineering to enhance human capacities has become so common among the richest 5 percent across the world that they have become a new species poised to control the rest more decisively than was possible in the past.

Our chance to control these threats with smart laws and global partnerships will be distant memories by then. But you did not know about this danger because not enough celebrities have tweeted about it!

We all need to refocus on the fundamental structural flaws that are disabling our political system from making effective laws and preventing too many Americans from learning the most basic things they need to be responsible citizens. We cannot fix the substantive problems without working political tools, and our tools are so broken that we neither diagnose most of the problems nor fix them.

What would we think of a mechanic who is so outraged by an expensive broken car headlight that he does not notice that the steering column is broken and that the tools he is taking to the headlight are rusted through? First things first: fix the political system and fix the education of citizens by fixing the Constitution.

Read this article:
COMMENTARY: Obsessed with Trump, our blindness to urgent issues grows - New Jersey Hills

Read More...

NJ Docs Beat Suit Over NY Patients Blindness – Law360

January 5th, 2020 8:42 am

Law360 (January 2, 2020, 6:03 PM EST) -- Two New Jersey-based doctors accused of causing a New Yorkers blindness with a botched procedure have escaped the suit after an Empire State appeals court ruled Thursday that the patient failed to prove the doctors principal business operations were in New York.

A four-judge Appellate Division panel for the First Department unanimously reversed a trial judges ruling that Drs. Henry K. Tsai and Brian H. Chon must face a suit accusing the physicians and others of providing negligent proton radiation therapy to Barbara Robins, which caused her to go blind in both eyes. Robins was undergoing treatment for a noncancerous brain...

In the legal profession, information is the key to success. You have to know whats happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.

TRY LAW360 FREE FOR SEVEN DAYS

Continue reading here:
NJ Docs Beat Suit Over NY Patients Blindness - Law360

Read More...

Experts warn sharing of makeup products can lead to blindness – Daily Nation

January 5th, 2020 8:42 am

By ANGELA OKETCHMore by this Author

Ladies, when you walk into that cosmetic store, do you request a new brush to test the make-up, or a new spreader for your lipstick or do you use what has already been used?

And do you share the same brush for your make-up or the same lipstick or lip gloss with your friends? How often do you clean the brushes you use? Do you check your product expiry date?

According to researchers, sharing of the products, not cleaning and using expired products, is dangerous and can cause either herpes or blindness.

According to findings published in the Journal of Applied Microbiology, the vast majority of in-use make-up products such as mascara, lip gloss, lipsticks and sponges are contaminated with potentially life-threatening superbugs because most of them are not cleaned and are used far beyond their expiry dates.

The new research, led by Dr Amreen Bashir and Prof Peter Lambert of Aston Universitys School of Life and Health Sciences, has shown that nine out of 10 in-use beauty products contain superbugs including E.coli and Staphylococci.

European Union guidance holds make-up brands to strict hygiene standards and states that E.coli, in particular, should not be found in any concentration in new cosmetic products. However, there is currently limited consumer protection around the risks of contaminating products while in use.

The study tested 467 make-up products, donated by people in the UK, for bacterial and fungal contamination and found that 90 per cent contained potentially deadly germs.

The make-up products examined (lipstick, lip gloss, eye liners, mascaras and beauty blenders) had between 100 and 1,000 individual bacteria, except for beauty blenders, which had an average of a million bacteria. As few as 100 cells of some bacteria can cause infection.

The products, when shared, could pose a significant health threat if used by a non-infected person.

According to Prof Lambert, both E.coli and Staphylococci were found in used eye-liner and mascara.

These bacteria can cause irritation and conjunctivitis (pink eye). Although the symptoms of conjunctivitis tend to be mildly itchy, watery eyes in extreme cases can lead to sight loss, he says.

And the germs causing conjunctivitis can spread to other parts of the body, which can trigger a more serious secondary infection.

The sponges used to apply skin foundation products were found to have the highest levels of potentially harmful bacteria, with the vast majority (93 per cent) not having ever been cleaned, despite more than two-thirds (64 per cent) being dropped on the floor at some point during use.

The researchers found these products (sponges) are particularly susceptible to contamination as they are often left damp after use, which creates an ideal breeding ground for harmful bacteria.

When the Sunday Nation sought the views of Kenyan women with regard to sharing, applying products in cosmetic stores and cleaning the sponges after use, most of them admitted that they always share and that some of the products take years before they are washed.

Could this be the reason I am struggling with acne that never goes away. I have never washed my sponge since I bought it last year.

I have been sharing make-up with my sister using the same sponge and lipsticks too. Both of us now have acne, says Tabitha Mulama.

For one Sylvia Atieno, whenever she wants to go out on a date and she is in town, she goes to any cosmetic shop for a makeover.

Unfortunately, they use brushes and lipsticks that they use on all customers. I have never thought that this could have an impact. From today I know, I better use my own products, she told the Sunday Nation team.

In a survey of cosmetic shops in the central business district, the Sunday Nation team noticed testers of lipsticks, powders, however, when one has to test the products they either buy their sponges to apply the powder or use what is provided, which has already been used by others.

There is no new spreader for the lipsticks. One uses an opened one without minding who might have used it before you.

The lipsticks and lip gloss in the sample study contained Staphylococci and various bacteria associated with faecal matter.

The bacteria could cause redness, swelling and inflammation of the lips, which can be treated with antibiotics or antibacterial creams.

If the germs spread to the blood or deeper tissues of the body, the infection can become life-threatening, he says.

Make-up brushes also have the potential to act as suitable homes for bacteria.

Often the brushes are dampened to help the application of eye shadows or foundation.

However, this environment has the potential to promote rapid bacterial growth.

The study revealed most beauty products come with preservatives to stop bacteria from growing, but they have a finite shelf life.

All cosmetics have expiry dates, which are calculated based on the length of time the preservatives in the product are able to control contamination.

However, the study shows people are using products beyond the expiry dates and allowing microbes to build up.

To avoid contamination, make sure you discard make-up that has passed the expiry period, dont apply make-up if you have an infection or broken skin, never share cosmetics with friends, and definitely avoid using make-up samples in stores, says Dr Bashir.

Recently, a Californian woman sued Sephora, a cosmetics company, claiming she contracted herpes from using one of the cosmetic stores lipstick samples.

Dr Bashir advised that to avoid germs from cosmetics, the sponges should be cleaned often with warm soapy water.

Follow this link:
Experts warn sharing of makeup products can lead to blindness - Daily Nation

Read More...

This Blind Veteran Not Only Climbs Mountains And Skydives, But Helps Other Injured Vets Accomplish Their Own Athletic Feats – Colorado Public Radio

January 5th, 2020 8:42 am

Soldier Steve Baskis was driving an armored vehicle in Baghdad in 2008 when he was gravely injured.

Shrapnel from an explosion cut through his optic nerves, blinding him. But since the accident, Baskis, now of Montrose, has climbed some of the world's tallest mountains, kayaked the Colorado River through the Grand Canyon, skydived and more.

"I was interested in becoming a special operation soldier. An unconventional soldier," he said. "And I think that's driven some of the things that I've pursued as a blind individual."

This month, Baskis plans to climb the tallest mountain in the Southern Hemisphere, Aconcagua in the Argentine Andes. It will be the 25th mountain he's climbed since losing his sight. He also runs a non-profit called Blind Endeavors to help other injured veterans stay active.

"I think you can reestablish, maybe, a new normal by exploring what's possible with the body that you have," he said.

Baskis talked to Colorado Matters about his athleticism, his foundation and other challenges veterans with disabilities face and learn from.

On mountain and rock climbing while blind:

"Usually I have a primary guy that leads in front of me. They could be just making noise with their footsteps, tapping things with trekking poles. I am hiking with trekking poles and feeling out the trail as I move, and they're telescopic. I'll ditch them if it gets real steep and scramble on my hands and knees.

Climbing is very tactile, and then occasionally I have a guide or someone behind me that'll just say, 'Steve, stay right. Hold that form.' Because he or she can see from behind."

On how traumatic events and disabilities can challenge people:

"When people go through a traumatic change, you then test yourself in different environments. It gives the person the ability to forge strength, mental fortitude strength, physical strength, resilience, courage, determination. And that all plays a huge role in your daily life, whether you're doing extreme things or mundane things.

I still am (paralyzed by fear) at times. It's interesting, staring into a dark world that's very still, stagnant. I think a lot of people that are blind don't move enough. And it might be because of blindness, it might be because of a lot of reasons, but I definitely have tried to rebel and fight against that feeling of being afraid to step out."

On how being blind and a veteran have taught him resilience:

"I think blindness has taught me that, to be okay with failure, or whatever people interpret as quitting, failure, or frustrations. There's a lot of failures in my life. I talk a lot about the positive. Everybody hears the positive, but absolutely, there's been struggles. I think the thing to remember is I look past that and I find a way to drive forward. And soldiers are taught that or experience that."

On the concept of "inspiration porn":

"That's an interesting term. There's so many phrases nowadays. If you're struggling in a place, and somehow you latch onto this idea of inspiration or motivation, it can be so beneficial for you. We're so influenced by the good and the bad in the world, and I'm still thinking about it to this day. How do people interpret and feel those things? And it's just dynamic, I think. It's a moment thing for everybody.

I try to lead by example, and I've never really tried to be inspiring. I've always wanted to live life and do great things, but I don't look at myself that way. A lot of these things are very challenging, and there are many struggles within climbing a mountain blind, or kayaking. A lot of bad days, a lot of negative feelings.

I think people focus on interesting things, like the feat, a physical feat, but it is important to remember that I am very proud of internal things that have allowed me to cope with the issue of being blind. And so, inspiration is something that is interpreted or felt by others, and I have no control over that."

Read this article:
This Blind Veteran Not Only Climbs Mountains And Skydives, But Helps Other Injured Vets Accomplish Their Own Athletic Feats - Colorado Public Radio

Read More...

Page 762«..1020..761762763764..770780..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick